The award will be presented Wednesday, October 11, as part of the conference co-organized by EPFL (Ecole Polytechnique Federale deLausanne) and ISREC (Swiss Institute for Experimental Cancer Research) and held on the EPFL campus.
With one foot firmly in fundamental research and the other in clinical work, Eduard Batlle has concentrated his efforts over the past decade on elucidating the mechanisms underlying the onset and progression of colorectal cancer. His independent research in three different areas of colorectal cancer – the study of intestinal stem cells and their malignant counterparts, identification of molecules that prevent malignancy of colorectal tumors, and identification of the genetic components involved in the spread of cancer cells to the liver -- represents an important contribution to our understanding of this deadly cancer. His published articles have been cited more than a thousand times, appearing in journals such as Nature, Nature Cell Biology and Cell. He is also the holder of a patent that is currently being commercially developed by two companies.
Since 2004, Eduard Batlle has led the oncology group at Barcelona’s Biomedical Research Institute (IRB) and is a professor in the Catalan Institute for Research and Advanced Studies. He held postdoctoral research positions in Germany at the University of Marburg and in the Hubrecht Laboratory of the Netherlands Institute for Developmental Biology. He specializes in the areas of molecular biology and colorectal cancer.
POTENTIAL FOR THERAPY
The purpose of the Debiopharm Life Sciences Award is to mentor and motivate innovative European life sciences researchers under the age of 40; this year, the prize is awarded for cancer research. The research must demonstrate innovative vision and originality and have high potential for therapeutic and commercial applications. The jury was composed of three representatives of Debiopharm including Rolland-Yves Mauvernay, the company’s President and Founder; three EPFL professors, including EPFL President Patrick Aebischer; and two external experts. The jury expressed admiration for the « extremely high level » of the candidates.
The Lausanne-based company Debiopharm, founded in 1979, is an independent drug-development company specializing in oncology and serious medical conditions. The company works closely with universities, research institutions, biotech firms or pharmaceutical companies to identify compounds with promising in-vivo results that could lead to new pharmaceutical products. With its considerable expertise and proven track record, Debiopharm shepherds potential products all the way through to the treatment phase. The company is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar® for prostate cancer treatment. These products are commercialized by pharmaceutical companies such as sanofi-aventis and Watson Pharmaceuticals, Inc.
- For additional information, contact: Dietrich Reinhard, EPFL School of Life Sciences; tel: 021 693 16 43, e-mail: email@example.com
- The official presentation ceremony will take place October 11 at 6 :45 pm at EPFL in room SG1, in the presence of Rolland-Yves Mauvernay, Founder and President of Debiopharm and Patrick Aebischer, President of EPFL.
Mary Parlange | alfa
How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
19.01.2018 | Materials Sciences
19.01.2018 | Health and Medicine
19.01.2018 | Physics and Astronomy